Using a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis

Program Overview

A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis (AD). Her dermatologist wants to take the next step and start her on a biologic, but she is worried about the patient’s ocular history and dupilumab’s conjunctivitis risk. Find out what the experts have to say about this doctor’s dilemma.

Credit Expired

CE Credit Expired

Expires: February 27, 2021

Target Audience

The target audience for this activity is US-based dermatologists, allergists, and immunologists, as well as NPs and PAs that diagnose and manage atopic dermatitis (AD). Primary care clinicians will also be included as a secondary audience.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, assessment of treatment response, and strategies to optimize short-term control and long-term management of the disease
Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Activity Faculty

Peter A. Lio, MD (Chair)

Assistant Professor, Clinical Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital
Chicago, IL

Mark Boguniewicz, MD

Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Denver, CO

Eric L. Simpson, MD, MCR

Professor, Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, OR

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Using a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Peter A. Lio, MD (Chair)

Mark Boguniewicz, MD

Eric L. Simpson, MD, MCR

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Collaboration Nation: Interprofessional Perspectives on Immunotherapy and Team-Based Care for Non-Melanoma Skin Cancer

Spinal Muscular Atrophy: An Interprofessional Approach

Tackling the Problem Head On: Key Considerations for CMV in the Post-Transplant Setting: A Care Team Forum®

Subscribe